Last reviewed · How we verify

Reckitt Benckiser LLC — Portfolio Competitive Intelligence Brief

Reckitt Benckiser LLC pipeline: 1 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 1 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Mucinex® Mucinex® marketed Expectorant Respiratory
Panadeine® Extra Panadeine® Extra phase 3 Opioid analgesic Opioid receptors Pain management
Nurofen Plus® Nurofen Plus® phase 3 NSAID/opioid combination analgesic COX-1/COX-2 (ibuprofen); mu opioid receptor (codeine) Pain Management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams University · 1 shared drug class
  2. Ajay Wasan, MD, Msc · 1 shared drug class
  3. Alza Corporation, DE, USA · 1 shared drug class
  4. American Health Research · 1 shared drug class
  5. Archimedes Development Ltd · 1 shared drug class
  6. Asbjørn Mohr Drewes · 1 shared drug class
  7. BioDelivery Sciences International · 1 shared drug class
  8. AdventHealth · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Reckitt Benckiser LLC:

Cite this brief

Drug Landscape (2026). Reckitt Benckiser LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/reckitt-benckiser-llc. Accessed 2026-05-14.

Related